Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab

References

• BassanRHoelzerDModern therapy of acute lymphoblastic leukemiaJ Clin Oncol201129553254321220592
   PubMed Web of Science ®Google Scholar
• DuXLChenQRecent advancements of bortezomib in acute lymphocytic leukemia treatmentActa Haematol2013129420721423295437
   PubMed Web of Science ®Google Scholar
• RobertsKGLiYPayne-TurnerDTargetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaN Engl J Med2014371111005101525207766
   PubMed Web of Science ®Google Scholar
• DeistingWRaumTKuferPBaeuerlePAMunzMImpact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM/CD3-bispecific antibody construct AMG 110PLoS One20151010e014166926510188
   PubMed Web of Science ®Google Scholar
• KlingerMBenjaminJKischelRStienenSZugmaierGHarnessing T cells to fight cancer with BiTE(R) antibody constructs – past developments and future directionsImmunol Rev2016270119320826864113
   PubMed Web of Science ®Google Scholar
• SchlegelPLangPZugmaierGPediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomabHaematologica20149971212121924727818
   PubMed Web of Science ®Google Scholar
• von StackelbergALocatelliFZugmaierGPhase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaJ Clin Oncol201634364381438927998223
   PubMed Web of Science ®Google Scholar
• KowolikCMToppMSGonzalezSCD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cellsCancer Res20066622109951100417108138
   PubMed Web of Science ®Google Scholar
• JensenMCPopplewellLCooperLJAntitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humansBiol Blood Marrow Transplant20101691245125620304086
   PubMed Web of Science ®Google Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2013National Cancer InstituteBethesda, MD Available from: http://seer.cancer.gov/csr/1975_2013/Accessed July 9, 2017
   Google Scholar
• SanzEMunozAMonserratJOrdering human CD34+CD10−CD19+ pre/pro-B-cell andProc Natl Acad Sci U S A2010107135925593020231472
   PubMedGoogle Scholar
• van DongenJJOrfaoAEuroFlow Consortium: resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicineLeukemia20122691899190722948488
   PubMed Web of Science ®Google Scholar
• RickertRCNew insights into pre-BCR and BCR signalling with relevance to B cell malignanciesNat Rev Immunol201313857859123883968
   PubMed Web of Science ®Google Scholar
• MullighanCGJehaSPeiDOutcome of children with hypo-diploid ALL treated with risk-directed therapy based on MRD levelsBlood2015126262896289926527677
   PubMed Web of Science ®Google Scholar
• MarksDIThe challenges of managing older patients with acute lymphoblastic leukemiaAm Soc Clin Oncol Educ Book2015e343e35125993195
   PubMedGoogle Scholar
• LukenbillJAdvaniASThe treatment of adolescents and young adults with acute lymphoblastic leukemiaCurr Hematol Malig Rep201382919723559026
   PubMedGoogle Scholar
• GokbugetNDombretHRiberaJMInternational reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaHaematologica2016101121524153327587380
   PubMed Web of Science ®Google Scholar
• TallenGRateiRMannGLong-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90J Clin Oncol201028142339234720385996
   PubMed Web of Science ®Google Scholar
• NagorsenDBargouRRuttingerDKuferPBaeuerlePAZugmaierGImmunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomabLeuk Lymphoma200950688689119455460
   PubMed Web of Science ®Google Scholar
• WuJFuJZhangMLiuDAFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapyJ Hematol Oncol201589626231785
   PubMed Web of Science ®Google Scholar
• FanGWangZHaoMLiJBispecific antibodies and their applicationsJ Hematol Oncol2015813026692321
   PubMed Web of Science ®Google Scholar
• BrinkmannUKontermannREThe making of bispecific antibodiesMAbs20179218221228071970
   PubMed Web of Science ®Google Scholar
• OffnerSHofmeisterRRomaniukAKuferPBaeuerlePAInduction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMol Immunol200643676377116360021
   PubMed Web of Science ®Google Scholar
• BrischweinKSchlerethBGullerBMT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumorsMol Immunol20064381129114316139892
   PubMed Web of Science ®Google Scholar
• HoffmannPHofmeisterRBrischweinKSerial killing of tumor cells by cytotoxic T cells redirected with a CD19−/CD3-bispecific single-chain antibody constructInt J Cancer200511519810415688411
   PubMed Web of Science ®Google Scholar
• ToppMSGokbugetNZugmaierGLong-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood2012120265185518723024237
   PubMed Web of Science ®Google Scholar
• ZugmaierGGokbugetNKlingerMLong-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentBlood2015126242578258426480933
   PubMed Web of Science ®Google Scholar
• ToppMSGokbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
   PubMed Web of Science ®Google Scholar
• BarlevALinVWKatzAHuKCongZBarberBEstimating long-term survival of adults with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab using historical dataAdv Ther201734114815527873237
   PubMed Web of Science ®Google Scholar
• KantarjianHSteinAGokbugetNBlinatumomab versus. chemotherapy for advanced acute lymphoblastic leukemiaN Engl J Med2017376983684728249141
   PubMed Web of Science ®Google Scholar
• MartinelliGDombretHChevallierPComplete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm multicenter study (ALCANTARA). Abstract #679Presented at: The 2015 ASH Annual MeetingDecember 7, 2015Orlando, FL
   Google Scholar
• ZhuMWuBBrandlCBlinatumomab, a bispecific T-cell engager (BiTE((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implicationsClin Pharmacokinet201655101271128827209293
   PubMed Web of Science ®Google Scholar
• KaplanJBGrischenkoMGilesFJBlinatumomab for the treatment of acute lymphoblastic leukemiaInvest New Drugs20153361271127926383529
   PubMed Web of Science ®Google Scholar
• BargouRLeoEZugmaierGTumor regression in cancer patients by very low doses of a T cell-engaging antibodyScience2008321589197497718703743
   PubMed Web of Science ®Google Scholar
• KlingerMBrandlCZugmaierGImmunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood2012119266226623322592608
   PubMed Web of Science ®Google Scholar
• WuJFuJZhangMLiuDBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaJ Hematol Oncol2015810426337639
   PubMed Web of Science ®Google Scholar
• ToppMSGokbugetNZugmaierGPhase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaJ Clin Oncol201432364134414025385737
   PubMed Web of Science ®Google Scholar
• TeacheyDTRheingoldSRMaudeSLCytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood2013121265154515723678006
   PubMed Web of Science ®Google Scholar
• NagorsenDKuferPBaeuerlePABargouRBlinatumomab: a historical perspectivePharmacol Ther2012136333434222940266
   PubMed Web of Science ®Google Scholar
• ToppMSGockbugetNSteinASCorrection to lancet oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 studyLancet Oncol2015164e158
   PubMedGoogle Scholar
• DarvishiBFarahmandLJaliliNMajidzadehAKBlinatumomab provoked fatal heart failureInt Immunopharmacol201641424627816725
   PubMed Web of Science ®Google Scholar
• ToppMSKuferPGokbugetNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
   PubMed Web of Science ®Google Scholar
• van ZelmMCReisliIvan derBMAn antibody-deficiency syndrome due to mutations in the CD19 geneN Engl J Med2006354181901191216672701
   PubMed Web of Science ®Google Scholar
• RobertsDMJonesRBSmithRMImmunoglobulin G replacement for the treatment of infective complications of rituximab- associated hypogammaglobulinemia in autoimmune disease: a case seriesJ Autoimmun201557242925586449
   PubMed Web of Science ®Google Scholar
• HolzelMBovierATutingTPlasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?Nat Rev Cancer201313536537623535846
   PubMed Web of Science ®Google Scholar
• BraigFBrandtAGoebelerMResistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane traffickingBlood2017129110010427784674
   PubMed Web of Science ®Google Scholar
• RayesAMcMastersRLO’BrienMMLineage switch in MLL-rearranged infant leukemia following CD19-directed therapyPediatr Blood Cancer20166361113111526914337
   PubMed Web of Science ®Google Scholar
• AldossISongJStillerTCorrelates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemiaAm J Hematol Epub2017511
   Google Scholar
• Pongers-WillemseMJVerhagenOJTibbeGJReal-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probesLeukemia19981212200620149844931
   PubMed Web of Science ®Google Scholar
• DuellJDittrichMBedkeTFrequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALLLeukemia Epub2017224
   Web of Science ®Google Scholar
• KohnkeTKrupkaCTischerJKnoselTSubkleweMIncrease of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabJ Hematol Oncol2015811126449653
   PubMed Web of Science ®Google Scholar
• FeuchtJKayserSGorodezkiDT-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blastsOncotarget2016747769027691927708227
   PubMed Web of Science ®Google Scholar
• RiberaJMFerrerARiberaJGenescaEProfile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemiaOnco Targets Ther201581567157426170691
   PubMed Web of Science ®Google Scholar
• GokbugetNZugmaierGKlingerMLong-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemiaHaematologica20171024e132e13528082340
   PubMed Web of Science ®Google Scholar